The research goal of Alex Marson’s lab is to understand the genetic circuits that control the function of cells in the human immune system, especially T cells. Marson and colleagues have developed new tools to accomplish efficient genome engineering in primary human immune cells with CRISPR. With this technology scientists can now readily rewrite specific sequences in human cells and interrogate the biological effects. These advances in genome editing will accelerate fundamental insights into how immune cells are “wired” and have potential to enhance the next generation of cell-based immunotherapies for cancer, infectious diseases, organ transplantation, and autoimmune diseases.
Areas of Expertise
Marson’s team is pioneering new CRISPR gene-editing technologies that offer faster, cheaper and more precise ways to re-write DNA programs in human immune cells. With these tools, the lab is engineering cells to treat a wide range of diseases. They are designing programs to make cells that can recognize and eliminate cancer, cells that are resistant to infections like HIV, and cells that can reduce inflammation in autoimmune diseases like multiple sclerosis, type 1 diabetes, and rheumatoid arthritis. Reprogrammed human immune cells are emerging as a new class of “living” medicines.
Director, Gladstone-UCSF Institute of Genomic Immunology
Senior Investigator, Gladstone Institutes
Professor, Medicine, UCSF
Center Director, The Parker Institute for Cancer Immunotherapy at Gladstone Institutes
Alexander Marson, MD, PhD, is the director of the Gladstone-UCSF Institute of Genomic Immunology, a senior investigator at Gladstone Institutes, and an associate professor in the Departments of Medicine and Microbiology and Immunology at UCSF.
Marson is interested in how DNA controls the behavior of cells in the human immune system. He uses the power of CRISPR technology to genetically engineer cells to fight cancer, autoimmune diseases, and infectious diseases.
He completed his undergraduate studies at Harvard University, and earned an MPhil in biological sciences from Cambridge. He earned his PhD at Whitehead Institute at MIT, where he worked with mentors Rick Young and Rudolf Jaenisch on transcriptional control of regulatory T cells and embryonic stem cells.
After completing his MD at Harvard Medical School and an internship and residency at the Brigham and Women’s Hospital, Marson joined UCSF in 2012 to complete clinical work as an infectious diseases fellow. He started his lab as a Sandler Faculty Fellow, before joining the faculty at UCSF and becoming scientific director of biomedicine at the Innovative Genomics Institute. He is also a Chan Zuckerberg Biohub Investigator and member of the Parker Institute for Cancer Immunotherapy.
Honors and Awards
2019 American Society of Clinical Investigators (ASCI) Member
2016 NIH/NIDA Avenir New Innovator Award
2016 Burroughs Wellcome Foundation Career Award for Medical Scientists
2016 American Society of Clinical Investigators (ASCI) Young Physician-Scientist Award
2010 James Tolbert Shipley Prize for Excellence and Accomplishment in Research, Harvard
2009 Sigma Xi, MIT
Administrative Program Manager